JRM

Journal of Radiology in Medicine is an international journal that published original research and articles in all areas of radiology. Its publishes original research articles, review articles, case reports, editorial commentaries, letters to the editor, educational articles, and conference/meeting announcements.

EndNote Style
Index
Review
The role of ADC value and ADC ratio in the diagnosis and prognostic evaluation of prostate cancer
Prostate cancer is the second most common malignancy in men after lung cancer and remains a major cause of cancer-related mortality. Although prostate-specific antigen testing has reduced mortality, its low specificity leads to overdiagnosis and unnecessary biopsies. Multiparametric magnetic resonance imaging has advanced prostate cancer evaluation by integrating anatomical, functional, and vascular imaging. Diffusion-weighted imaging and apparent diffusion coefficient measurements provide objective markers of tumor cellularity, which correlate with Gleason score and International Society of Urological Pathology Grade Group. To summarize the diagnostic and prognostic role of absolute apparent diffusion coefficient values and the apparent diffusion coefficient ratio in prostate cancer. A narrative review of the literature from 2006 to 2025 was conducted through PubMed and Scopus using terms related to prostate cancer, diffusion-weighted imaging, apparent diffusion coefficient, ratio, and prostate-specific antigen density. Twenty-seven references were included, ranging from early technical reports to recent meta-analyses and guideline-based studies. Absolute apparent diffusion coefficient values decrease with increasing tumor aggressiveness but are limited by technical and patient-related variability. The apparent diffusion coefficient ratio, calculated as the lesion value relative to normal prostate tissue, reduces variability and improves diagnostic accuracy, particularly in Prostate Imaging Reporting and Data System category 3 lesions. When combined with prostate-specific antigen density, it increases accuracy for detecting clinically significant cancer and decreases unnecessary biopsies. Apparent diffusion coefficient and the apparent diffusion coefficient ratio are promising non-invasive imaging biomarkers that improve lesion characterization, biopsy selection, and prognostic evaluation in prostate cancer. Future integration with artificial intelligence, radiomics, and radiogenomics may enhance personalized patient management.


1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10. 3322/caac.21660
2. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-1328. doi:10.1056/NEJMoa0810084
3. Turkbey B, Pinto PA, Choyke PL. Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol. 2009;6(4):191-203. doi:10.1038/nrurol.2009.27
4. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033
5. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259(2):453-461. doi: 10.1148/radiol.11091409
6. Donati OF, Mazaheri Y, Afaq A, et al. Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology. 2014;271(1):143-152. doi:10.1148/radiol. 13130973
7. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology. 2011;259(3):775-784. doi:10.1148/radiol. 11102066
8. Meyer HJ, Wienke A, Surov A. Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient-a systematic review and meta analysis. BMC Cancer. 2020; 20(1):482. doi: 10.1186/s12885-020-06942-x
9. Barrett T, Priest AN, Lawrence EM, et al. Ratio of tumor to normal prostate tissue apparent diffusion coefficient as a method for quantifying DWI of the prostate. AJR Am J Roentgenol. 2015;205(6):W585-W593. doi:10.2214/AJR.15.14338
10. Woo S, Kim SY, Cho JY, Kim SH. Preoperative evaluation of prostate cancer aggressiveness: using ADC and ADC ratio in determining Gleason score. AJR Am J Roentgenol. 2016;207(1):114-120. doi:10.2214/AJR.15.15894
11. Gaur S, Harmon S, Rosenblum L, et al. Can apparent diffusion coefficient values assist PI-RADS version 2 DWI scoring? A correlation study using the PI-RADSv2 and International Society of Urological Pathology systems. AJR Am J Roentgenol. 2018;211(1):W33-W41. doi:10. 2214/AJR.17.18702
12. Bonekamp D, Kohl S, Wiesenfarth M, et al. Radiomic machine learning for characterization of prostate lesions with MRI: comparison to ADC values. Radiology. 2018;289(1):128-137. doi:10.1148/radiol.2018173064
13. Lucarelli NM, Villanova I, Maggialetti N, et al. Quantitative ADC: an additional tool in the evaluation of prostate cancer? J Pers Med. 2023; 13(9):1378. doi:10.3390/jpm13091378
14. Agrotis G, Pooch E, Abdelatty M, et al. Diagnostic performance of ADC and ADCratio in MRI-based prostate cancer assessment: a systematic review and meta-analysis. Eur Radiol. 2025;35(1):404-416. doi:10.1007/s00330-024-10890-6
15. Donati OF, Afaq A, Vargas HA, et al. Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score. Clin Cancer Res. 2014;20(14):3705-3711. doi:10.1158/1078-0432.CCR-14-0044
16. Scialpi M, Martorana E, Scialpi P, et al. MRI apparent diffusion coefficient (ADC): a biomarker for prostate cancer after radiation therapy. Turk J Urol. 2021;47(6):448-451. doi:10.5152/tud.2021.21274
17. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(2):425-430. doi:10.1016/j.ijrobp.2007.06.029
18. Wen J, Ji Y, Han J, Shen X, Qiu Y. Inter-reader agreement of the prostate imaging reporting and data system version v2.1 for detection of prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:1013941. doi:10.3389/fonc.2022.1013941
19. Park KJ, Choi SH, Kim MH, Kim JK, Jeong IG. Performance of prostate imaging reporting and data system version 2.1 for diagnosis of prostate cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2021;54(1):103-112. doi:10.1002/jmri.27546
20. Peng Y, Jiang Y, Yang C, et al. Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score-a computer-aided diagnosis development study. Radiology. 2013;267(3):787-796. doi:10. 1148/radiol.13121454
21. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF 2nd. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol. 2010; 194(4):W316-W322. doi:10.2214/AJR.09.2651
22. Verma S, Rajesh A, Morales H, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol. 2011; 196(2):374-381. doi:10.2214/AJR.10.4441
23. Washino S, Okochi T, Saito K, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU Int. 2017;119(2):225-233. doi:10.1111/bju.13465
24. Spadarotto N, Sauck A, Hainc N, Keller I, John H, Hohmann J. Quantitative evaluation of apparent diffusion coefficient values, ISUP grades and prostate-specific antigen density values of potentially malignant PI-RADS lesions. Cancers (Basel). 2023;15(21):5183. doi:10. 3390/cancers15215183
25. Karaarslan E, Kus AA, Alis D et al. Performance of apparent diffusion coefficient values and ratios for the prediction of prostate cancer aggressiveness across different MRI acquisition settings. Diagn Interv Radiol. 2022;28(1):12-20. doi:10.5152/dir.2022.20732
26. He D, Wang X, Fu C, et al. MRI-based radiomics models to assess prostate cancer, extracapsular extension and positive surgical margins. Cancer Imaging. 2021;21(1):46. doi:10.1186/s40644-021-00414-6
27. Akin O, Gultekin DH, Vargas HA, et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol. 2011;21(9):1970-1978. doi:10.1007/s00330-011-2130-6
28. Kwon D, Reis IM, Breto AL, et al. Classification of suspicious lesions on prostate multiparametric MRI using machine learning. J Med Imaging (Bellingham). 2018;5(3):034502. doi:10.1117/1.JMI.5.3.034502
29. Zhang L, Tang M, Chen S, Lei X, Zhang X, Huan Y. A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. Eur Radiol. 2017;27(12):5204-5214. doi:10.1007/s00330-017-4843-7
30. Park SY, Kim CK, Park BK, Lee HM, Lee KS. Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results. Eur Radiol. 2011;21(5):1111-1118. doi:10.1007/s00330-010-1999-9
Volume 3, Issue 1, 2026
Page : 22-27
_Footer